What are the recent trends in market size and growth for the gm1 gangliosidosis market?
The GM1 gangliosidosis market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.57 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to increase in number of patients suffering from gm1 gangliosidosis, growing area of focus in the gm1 gangliosidosis space, rising prevalence of rare disease awareness, rising popularity of patient-centric research, and increasing focus on early intervention.
The GM1 gangliosidosis market size is expected to see rapid growth in the next few years. It will grow to $0.87 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing gm1 gangliosidosis cases, rising lysosomal storage disorder, rising number of clinical trials, increasing focus on gene therapy and editing, increasing personalized and precision medicine, and rising adoption of genetic screening programs. Major trends in the forecast period include advancements in gene-editing technologies, integration of technology in healthcare, advancement in diagnostic techniques, advanced formulations, and advancements in genetic therapies.
Get Your Free Sample of The Global GM1 Gangliosidosis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp
How have varous drivers impacted the growth of the gm1 gangliosidosis market?
The increasing adoption of gene therapy is expected to fuel the growth of the GM1 gangliosidosis market going forward. Gene therapy is a medical treatment that involves altering or replacing genes within a person’s cells to treat or prevent disease. The increasing adoption of gene therapy is driven by advancements in genetic research, improved treatment outcomes for previously untreatable conditions, and growing regulatory support for innovative therapies. Gene therapy for GM1 gangliosidosis involves delivering a functional copy of the defective gene (GLB1) to patient cells to restore ß-galactosidase enzyme activity and reduce toxic substrate buildup. For instance, in April 2024, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, in the fourth quarter, the number of phase III gene therapy clinical trials rose by 10%, marking the first quarterly increase since the third quarter of 2022. Therefore, the increasing adoption of gene therapy is driving the growth of the GM1 gangliosidosis market.
What are the primary segments of the gm1 gangliosidosis market?
The GM1 gangliosidosis market covered in this report is segmented –
1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis
2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy
3) By End-User: Research Institutes, Hospitals, Other End-Users
Subsegments:
1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset
2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset
3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report
Which firms are leading the gm1 gangliosidosis market?
Major companies operating in the GM1 gangliosidosis market are Pfizer Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc., CRISPR Therapeutics AG, REGENXBIO Inc., Passage Bio Inc., Orchard Therapeutics plc, AVROBIO Inc., uniQure N.V., GEMMA Biotherapeutics Inc., Lysogene S.A., AZAFAROS B.V., BioStrategies LC, Sio Gene Therapies Inc., Gain Therapeutics Inc., Dorphan S.A., bluebird bio Inc., Axovant Gene Therapies Ltd., SphinCS GmbH.
How will industry trends affect the trajectory of the gm1 gangliosidosis market?
Major companies operating in the GM1 gangliosidosis market are focusing on strategic partnerships to sustain their position in the market. Strategic partnerships play a crucial role in advancing gene therapy development by combining expertise, resources, and technologies to accelerate research, clinical trials, and commercialization. For instance, in October 2024, GEMMA Biotherapeutics Inc., a US-based biotechnology company, partnered with Oswaldo Cruz Foundation (Fiocruz), a Brazil-based health research institution, to develop gene therapies for rare diseases, including GM1 gangliosidosis. The agreement involves up to $100 million in funding from Fiocruz for clinical research and manufacturing, aimed at making these advanced therapies accessible through Brazil’s public healthcare system. This collaboration emphasizes technology transfer and aims to democratize access to treatments that were previously limited to higher-income populations.
Which geographic trends are shaping the gm1 gangliosidosis market, and which region has the highest market share?
North America was the largest region in the GM1 gangliosidosis market in 2024. The regions covered in the GM1 gangliosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The GM1 Gangliosidosis Market Report 2025 Offer?
The gm1 gangliosidosis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
GM1 gangliosidosis is a rare, inherited neurodegenerative disorder caused by a deficiency of the ß-galactosidase (GLB1) enzyme, leading to toxic accumulation of GM1 gangliosides in the brain and other tissues. It results in progressive neurological decline, developmental delays, muscle weakness, and organ enlargement.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21194
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
